

AMENDMENTS TO THE CLAIMS

Claims 1-10: (Cancelled)

B2
Claim 11: (Currently amended) A binding compound comprising an antibody binding site which specifically binds to:

- a) at least 17 contiguous amino acids from the signal processed form of SEQ ID NO: 215;
- b) at least 17 contiguous amino acids from the signal processed form of SEQ ID NO: 4;
- c) at least 17 contiguous amino acids from the signal processed form of SEQ ID NO: 6;
- d) at least 17 contiguous amino acids from the signal processed form of SEQ ID NO: 8;
- e) at least 17 contiguous amino acids from the signal processed form of SEQ ID NO: 13;
- f) at least 17 contiguous amino acids from the signal processed form of SEQ ID NO: 17;

or

- hc) at least 17 contiguous amino acids from the signal processed form of SEQ ID NO: 19.

Claim 12: (Currently amended) The binding compound of Claim 11, wherein:

- a) said antibody binding site is:

- 1) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 2;
 - 2) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 4;
 - 3) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 6;
 - 4) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 8;
 - 5) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 13;

b2
cont'

16) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 15;

27) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 17;

38) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 19; or

b) said binding compound is:

- 1) an antibody molecule;
- 2) present in a polyclonal antiserum;
- 3) detectably labeled;
- 4) sterile; or
- 5) in a buffered composition.

Claim 13: (Original) A method using the binding compound of Claim 11, comprising contacting said binding compound with a biological sample comprising an antigen, thereby forming a binding compound:antigen complex.

Claim 14: (Original) The method of Claim 13, wherein said biological sample is from a human, and wherein said binding compound is an antibody.

Claim 15: (Currently amended) A detection kit comprising said binding compound of Claim 12, and:

- a) instructional material for the use of said binding compound for said detection; or
- b) a compartment providing segregation of said binding compound from other kit reagents.

Claims 16-20: (Cancelled)

B2
cont.

Claim 21: (New) The binding compound of claim 11, wherein the binding compound is a monoclonal antibody.

Claim 22: (New) The binding compound of claim 11, wherein the binding compound is a humanized antibody.